X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5411) 5411
Book Chapter (29) 29
Magazine Article (17) 17
Book Review (3) 3
Dissertation (3) 3
Newsletter (3) 3
Book / eBook (2) 2
Conference Proceeding (1) 1
Newspaper Article (1) 1
Publication (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4153) 4153
male (3303) 3303
index medicus (2701) 2701
middle aged (1523) 1523
phosphodiesterase inhibitors - therapeutic use (1453) 1453
sildenafil citrate (1449) 1449
animals (1321) 1321
erectile dysfunction - drug therapy (1265) 1265
female (1173) 1173
erectile dysfunction (1165) 1165
adult (1162) 1162
sildenafil (1102) 1102
aged (1048) 1048
phosphodiesterase inhibitors - adverse effects (1014) 1014
treatment outcome (989) 989
pharmacology & pharmacy (920) 920
urology & nephrology (878) 878
piperazines - therapeutic use (790) 790
tadalafil (712) 712
piperazines - adverse effects (706) 706
phosphodiesterase 5 inhibitors - therapeutic use (679) 679
phosphodiesterase inhibitors - pharmacology (679) 679
impotence (673) 673
purines (660) 660
sulfones (654) 654
double-blind (609) 609
double-blind method (574) 574
phosphodiesterase (556) 556
phosphodiesterase inhibitors - administration & dosage (514) 514
drug therapy (511) 511
care and treatment (495) 495
men (481) 481
efficacy (468) 468
rats (464) 464
risk factors (432) 432
safety (426) 426
analysis (407) 407
erectile dysfunction - etiology (405) 405
cardiac & cardiovascular systems (403) 403
phosphodiesterase inhibitors (401) 401
dose-response relationship, drug (395) 395
sulfones - therapeutic use (388) 388
phosphodiesterase 5 inhibitors - adverse effects (386) 386
mice (371) 371
research (358) 358
medicine & public health (357) 357
therapy (336) 336
drug therapy, combination (333) 333
pulmonary hypertension (330) 330
administration, oral (325) 325
health aspects (324) 324
hypertension, pulmonary - drug therapy (324) 324
piperazines - administration & dosage (322) 322
time factors (319) 319
nitric-oxide (318) 318
sulfones - adverse effects (308) 308
medicine, general & internal (307) 307
clinical trials (304) 304
hypertension (295) 295
respiratory system (294) 294
purines - therapeutic use (292) 292
vasodilator agents - therapeutic use (287) 287
vardenafil dihydrochloride (283) 283
vardenafil (282) 282
inflammation (279) 279
prospective studies (275) 275
piperazines - pharmacology (272) 272
nitric oxide (265) 265
disease models, animal (263) 263
phosphodiesterase 5 inhibitors - administration & dosage (262) 262
phosphodiesterase 5 inhibitors (250) 250
penile erection - drug effects (249) 249
dosage and administration (247) 247
abridged index medicus (245) 245
carbolines - therapeutic use (242) 242
erectile dysfunction - physiopathology (229) 229
aged, 80 and over (226) 226
internal medicine (225) 225
phosphodiesterase inhibitor (225) 225
quality of life (225) 225
inhibitors (223) 223
randomized controlled trials as topic (223) 223
purines - adverse effects (222) 222
drug interactions (219) 219
quality-of-life (219) 219
adolescent (217) 217
oral sildenafil (216) 216
surgery (214) 214
expression (213) 213
carbolines - adverse effects (212) 212
neurosciences (205) 205
phosphodiesterase 5 inhibitors - pharmacology (204) 204
phosphodiesterases (204) 204
sulfones - administration & dosage (203) 203
disease (200) 200
drug administration schedule (200) 200
imidazoles - therapeutic use (199) 199
young adult (199) 199
3',5'-cyclic-gmp phosphodiesterases - antagonists & inhibitors (198) 198
prevalence (198) 198
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5228) 5228
German (87) 87
Chinese (38) 38
French (36) 36
Spanish (31) 31
Japanese (29) 29
Russian (24) 24
Portuguese (7) 7
Danish (5) 5
Italian (5) 5
Dutch (4) 4
Finnish (4) 4
Korean (4) 4
Swedish (4) 4
Hebrew (3) 3
Hungarian (2) 2
Norwegian (2) 2
Polish (2) 2
Bulgarian (1) 1
Czech (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane Database of Systematic Reviews, ISSN 1469-493X, 09/2017, Volume 2017, Issue 9, p. CD002309
.... Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD... 
Aminopyridines | Lungs & airways | Administration, Oral | Pulmonary Disease, Chronic Obstructive | Cyclopropanes | Disease Progression | Randomized Controlled Trials as Topic | Forced Expiratory Volume | Chronic obstructive pulmonary disease (stable) | Phosphodiesterase 4 Inhibitors | Quality of Life | Nitriles | Chronic obstructive pulmonary disease, stable ‐ pharmacotherapy | Cyclohexanecarboxylic Acids | Benzamides | Medicine General & Introductory Medical Sciences | Phosphodiesterases | Other medications | COST-EFFECTIVENESS ANALYSIS | Humans | LUNG-FUNCTION | Pulmonary Disease, Chronic Obstructive [drug therapy] | CORTICOSTEROID/LONG-ACTING BETA-AGONIST | MEDICINE, GENERAL & INTERNAL | Benzamides [administration & dosage; adverse effects] | Cyclopropanes [administration & dosage; adverse effects] | Aminopyridines [administration & dosage; adverse effects] | Forced Expiratory Volume [drug effects] | DOUBLE-BLIND | EXACERBATIONS | Phosphodiesterase 4 Inhibitors [administration & dosage; adverse effects] | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | Nitriles [administration & dosage; adverse effects] | COPD PATIENTS | LABA/LAMA/ICS TREATMENT | ROFLUMILAST | Cyclohexanecarboxylic Acids [administration & dosage; adverse effects] | Aminopyridines - administration & dosage | Forced Expiratory Volume - drug effects | Cyclohexanecarboxylic Acids - adverse effects | Aminopyridines - adverse effects | Cyclohexanecarboxylic Acids - administration & dosage | Cyclopropanes - adverse effects | Nitriles - administration & dosage | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Nitriles - adverse effects | Benzamides - adverse effects | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Current Opinion in Pharmacology, ISSN 1471-4892, 2012, Volume 12, Issue 3, pp. 275 - 286
.... ► Dose limiting side effects of nausea, vomiting and weight gain might limit the utility of oral formulations of PDE4 inhibitors... 
Internal Medicine | Medical Education | OBSTRUCTIVE PULMONARY-DISEASE | CYCLIC-AMP | DIFFERENTIAL EXPRESSION | INDUCED AIRWAY INFLAMMATION | IN-VIVO EFFICACY | ARTERIAL-HYPERTENSION | HUMAN LUNG FIBROBLASTS | CD4(+) T-CELLS | PHARMACOLOGY & PHARMACY | NECROSIS-FACTOR-ALPHA | PHOSPHODIESTERASE TYPE-4 INHIBITOR | Phosphodiesterase Inhibitors - therapeutic use | Asthma - metabolism | Phosphodiesterase Inhibitors - adverse effects | Phosphodiesterase 3 Inhibitors - pharmacology | Humans | Respiratory System - enzymology | Drug Therapy, Combination - adverse effects | Phosphodiesterase 4 Inhibitors - adverse effects | Pulmonary Disease, Chronic Obstructive - metabolism | Phosphodiesterase 3 Inhibitors - adverse effects | Molecular Targeted Therapy - adverse effects | Phosphoric Diester Hydrolases - metabolism | Asthma - enzymology | Phosphodiesterase 4 Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - pharmacology | Phosphodiesterase 3 Inhibitors - therapeutic use | Phosphodiesterase 4 Inhibitors - pharmacology | Asthma - drug therapy | Phosphoric Diester Hydrolases - chemistry | Pulmonary Disease, Chronic Obstructive - enzymology | Animals | Respiratory System - metabolism | Respiratory System - drug effects | Isoenzymes - antagonists & inhibitors | Pulmonary Disease, Chronic Obstructive - drug therapy | Respiratory tract diseases | Respiratory agents | Care and treatment | Drug therapy | Lung diseases
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
...s: ED, phosphodiesterase type 5 (PDE5) inhibitors, oral drug therapy, intracavernosal injection therapy, transurethral therapy, topical therapy, and vacuum-erection therapy/constriction devices... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 3, pp. 494 - 503.e6
Journal Article
Respiratory Research, ISSN 1465-9921, 12/2011, Volume 12, Issue 1, pp. 1 - 10
.... Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD but its effect on exacerbations in unselected populations was inconclusive... 
Medicine & Public Health | Pneumology/Respiratory System | OBSTRUCTIVE PULMONARY-DISEASE | RANDOMIZED CONTROLLED-TRIAL | RESPIRATORY SYSTEM | BURDEN | EPIDEMIOLOGY | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Lung - enzymology | Patient Selection | Cyclopropanes - therapeutic use | Forced Expiratory Volume | Benzamides - administration & dosage | Clinical Trials, Phase III as Topic | Anti-Inflammatory Agents - adverse effects | Benzamides - therapeutic use | Multicenter Studies as Topic | Aminopyridines - therapeutic use | Cyclopropanes - administration & dosage | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Female | Benzamides - adverse effects | Aminopyridines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Risk Factors | Proportional Hazards Models | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Lung - physiopathology | Pulmonary Disease, Chronic Obstructive - enzymology | Randomized Controlled Trials as Topic | Lung - drug effects | Aged | Research Design | Pulmonary Disease, Chronic Obstructive - drug therapy | Complications and side effects | Lung diseases, Obstructive | Patient outcomes | Dosage and administration | Research | Roflumilast | Drug therapy | Care and treatment | Bronchitis | Analysis | Studies | Hospitals | Statistical analysis | Mortality | Standard deviation | Hospitalization | Clinical medicine | Regression analysis | Manuscripts | Acquisitions & mergers
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2017, Volume 23, Issue 5, pp. 1186 - 1192
...), as well as to capture any potential antitumor activity of the PDE4 inhibitor roflumilast in combination with prednisone in patients with advanced B-cell malignancies... 
IN-VITRO | ONCOLOGY | ACUTE LYMPHOBLASTIC-LEUKEMIA | GENE-EXPRESSION | IBRUTINIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | LYMPHOMA | RECEPTOR | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | TARGETING BTK | T-CELLS | Humans | Middle Aged | Aminopyridines - adverse effects | Male | Cyclopropanes - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Drug-Related Side Effects and Adverse Reactions - pathology | Benzamides - administration & dosage | Cyclopropanes - administration & dosage | Neoplasms - genetics | Phosphodiesterase 4 Inhibitors - administration & dosage | Phosphodiesterase 4 Inhibitors - adverse effects | Aged, 80 and over | Adult | Cyclic Nucleotide Phosphodiesterases, Type 4 - drug effects | Female | B-Lymphocytes - pathology | Benzamides - adverse effects | Aminopyridines - administration & dosage | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | B-Lymphocytes - drug effects | Maximum Tolerated Dose | Aged | Neoplasms - pathology | Anorexia | Pharmacodynamics | Phosphodiesterase IV | Fatigue | AKT protein | Pharmacology | Prednisone | Kinases | Patients | 1-Phosphatidylinositol 3-kinase | Anticancer properties | Inhibitors | Lymphocytes B | Experimental design | Quality | Safety engineering | Biomarkers | Antitumor activity | Safety | Pharmacokinetics | Cancer | Neutropenia | Phosphodiesterase | clinical trial | cyclic-AMP | AKT | PI3K | phosphodiesterase 4 | Lymphoma
Journal Article
Pulmonary Pharmacology & Therapeutics, ISSN 1094-5539, 2010, Volume 23, Issue 4, pp. 235 - 256
Abstract After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast... 
Medical Education | Pulmonary/Respiratory | Phosphodiesterase 4 | Inflammation | Roflumilast | Oral therapy | COPD | Preclinical pharmacology | SMOKE-INDUCED EMPHYSEMA | OXIDATIVE STRESS | FIBROBLAST-MEDIATED CONTRACTION | NECROSIS-FACTOR-ALPHA | ADHESION MOLECULES | PDE4 INHIBITORS | TRANSMEMBRANE CONDUCTANCE REGULATOR | RESPIRATORY SYSTEM | EPIDERMAL-GROWTH-FACTOR | PHARMACOLOGY & PHARMACY | ENDOTHELIAL CELL-INTERACTIONS | CIGARETTE-SMOKE | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Administration, Oral | Humans | Aminopyridines - adverse effects | Phosphodiesterase Inhibitors - pharmacology | Pulmonary Disease, Chronic Obstructive - physiopathology | Cyclopropanes - adverse effects | Inflammation - etiology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Cyclopropanes - therapeutic use | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Inflammation - drug therapy | Aminopyridines - pharmacology | Phosphodiesterase 4 Inhibitors | Benzamides - pharmacology | Drug Evaluation, Preclinical | Benzamides - adverse effects | Cyclopropanes - pharmacology | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Isoenzymes | Comorbidity | Respiratory agents | Pharmacology | T cells | Macrophages | Pulmonary hypertension | Endothelium | Metabolites | Universities and colleges | Smoking
Journal Article